Abeona’s Q1 ZEVASKYN Revenue Rises to $8.7M; Licenses $7M PSMA Therapy
In Q1 2026 Abeona net product revenue rose to $8.7 million from $2.4 million in Q4 2025, supporting three ZEVASKYN patient treatments and expansion of its QTC network to six sites. The company in-licensed PSMA-targeted T-cell asset ABO-701 for $7 million and plans an IND filing in H2 2027.
1. Q1 2026 Financial Highlights
Abeona reported net product revenue of $8.7 million for the quarter ended March 31, 2026, up from $2.4 million in Q4 2025. Cost of sales increased to $2.7 million, reflecting three ZEVASKYN treatments versus one in the prior quarter, and net loss widened to $17.1 million; cash and equivalents stood at $168.3 million.
2. ZEVASKYN Commercial Expansion
Three patients completed ZEVASKYN treatment in Q1, with one treatment already in Q2 and six additional biopsies planned. The qualified treatment center network grew to six sites with New York-Presbyterian/Columbia and Children’s Hospital of Philadelphia added, and coverage policies now extend to 95% of commercially insured U.S. lives.
3. Pipeline Update and Licensing
Abeona in-licensed ABO-701, a PSMA-targeted engineered T-cell therapy, for a $7 million upfront payment, securing rights to a Synthetic Immune Receptor platform aimed at advanced prostate cancer. The company expects to file an IND in the second half of 2027 while refocusing resources away from its in-house ophthalmology programs.